Robert Chiascione, MD
Internal Medicine · Las Vegas, NVNPI 1710935697
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,398 of the $174,231 with a category attached, or 84.0%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 83.6% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $48,359, more than ten times the $3,377 reported in 2019. Among internal medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,225 payments — averaging $142.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$146K
- AbbVie$6K
- AstraZeneca$4K
- Novo Nordisk$2K
- Boehringer Ingelheim$2K
- GSK$2K
- plus $14K from 54 others
What the payments were for
- Consulting fees$146,39884%
- Food & beverage$27,14916%
- Education$6840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,231 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $88,575 |
| MounjaroTirzepatide | 40 | $54,666 |
| JardianceEmpagliflozin | 46 | $48,088 |
| FarxigaDapagliflozin Propanediol | 53 | $45,456 |
| RybelsusSemaglutide | 44 | $44,698 |
| XareltoRivaroxaban | 45 | $34,962 |
| MyrbetriqMirabegron | 55 | $34,699 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $24,984 |
| OzempicSemaglutide | 17 | $18,067 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $13,898 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $13,226 |
| BrilintaTicagrelor | 25 | $12,087 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,787 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $10,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Dilantin | $679 | $90,235109 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort, Breztri Aerosphere | $3,725 | $76,906126 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $1,536 | $75,21277 claims |
| Novo NordiskRybelsus, Ozempic | $2,461 | $62,76561 claims |
| Lilly USA, LLCMounjaro | $1,084 | $54,66640 claims |
| Johnson & JohnsonXarelto | $1,193 | $34,96245 claims |
| Astellas Pharma US IncMyrbetriq | $1,119 | $34,69955 claims |
| GSKTrelegy Ellipta | $1,524 | $24,98420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $145,704 | $10,38820 claims |
| AbbVieSynthroid | $5,529 | $7,77665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
- Henry WangLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.